The impact of hybrid immunity on immune responses after SARS-CoV-2 vaccination in persons with multiple sclerosis treated with disease-modifying therapies.
SARS-CoV-2
cellular immunity
humoral immunity
multiple sclerosis
vaccination
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
12 2023
12 2023
Historique:
revised:
22
06
2023
received:
09
11
2022
accepted:
27
07
2023
medline:
10
11
2023
pubmed:
31
7
2023
entrez:
31
7
2023
Statut:
ppublish
Résumé
Hybrid immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) develops from a combination of natural infection and vaccine-generated immunity. Multiple sclerosis (MS) disease-modifying therapies (DMTs) have the potential to impact humoral and cellular immunity induced by SARS-CoV-2 vaccination and infection. The aims were to compare antibody and T-cell responses after SARS-CoV-2 mRNA vaccination in persons with MS (pwMS) treated with different DMTs and to assess differences between naïvely vaccinated pwMS and pwMS with hybrid immunity vaccinated following a previous SARS-CoV-2 infection. Antibody and T-cell responses were determined in pwMS at baseline and 4 and 12 weeks after the second dose of SARS-CoV-2 vaccination in 143 pwMS with or without previous SARS-CoV-2 infection and 40 healthy controls (HCs). The MS cohort comprised natalizumab (n = 22), dimethylfumarate (n = 23), fingolimod (n = 38), cladribine (n = 30), alemtuzumab (n = 17) and teriflunomide (n = 13) treated pwMS. Immunoglobulin G antibody responses to SARS-CoV-2 antigens were measured using a multiplex bead assay and FluoroSpot was used to assess T-cell responses (interferon γ and interleukin 13). Humoral and T-cell responses to vaccination were comparable between naïvely vaccinated HCs and pwMS treated with natalizumab, dimethylfumarate, cladribine, alemtuzumab and teriflunomide, but were suppressed in fingolimod-treated pwMS. Both fingolimod-treated pwMS and HCs vaccinated following a previous SARS-CoV-2 infection had higher antibody levels 4 weeks after vaccination compared to naïvely vaccinated individuals. Antibody and interferon γ levels 12 weeks after vaccination were positively correlated with time from last treatment course of cladribine. These findings are of relevance for infection risk mitigation and for vaccination strategies amongst pwMS undergoing DMT.
Sections du résumé
BACKGROUND AND PURPOSE
Hybrid immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) develops from a combination of natural infection and vaccine-generated immunity. Multiple sclerosis (MS) disease-modifying therapies (DMTs) have the potential to impact humoral and cellular immunity induced by SARS-CoV-2 vaccination and infection. The aims were to compare antibody and T-cell responses after SARS-CoV-2 mRNA vaccination in persons with MS (pwMS) treated with different DMTs and to assess differences between naïvely vaccinated pwMS and pwMS with hybrid immunity vaccinated following a previous SARS-CoV-2 infection.
METHODS
Antibody and T-cell responses were determined in pwMS at baseline and 4 and 12 weeks after the second dose of SARS-CoV-2 vaccination in 143 pwMS with or without previous SARS-CoV-2 infection and 40 healthy controls (HCs). The MS cohort comprised natalizumab (n = 22), dimethylfumarate (n = 23), fingolimod (n = 38), cladribine (n = 30), alemtuzumab (n = 17) and teriflunomide (n = 13) treated pwMS. Immunoglobulin G antibody responses to SARS-CoV-2 antigens were measured using a multiplex bead assay and FluoroSpot was used to assess T-cell responses (interferon γ and interleukin 13).
RESULTS
Humoral and T-cell responses to vaccination were comparable between naïvely vaccinated HCs and pwMS treated with natalizumab, dimethylfumarate, cladribine, alemtuzumab and teriflunomide, but were suppressed in fingolimod-treated pwMS. Both fingolimod-treated pwMS and HCs vaccinated following a previous SARS-CoV-2 infection had higher antibody levels 4 weeks after vaccination compared to naïvely vaccinated individuals. Antibody and interferon γ levels 12 weeks after vaccination were positively correlated with time from last treatment course of cladribine.
CONCLUSION
These findings are of relevance for infection risk mitigation and for vaccination strategies amongst pwMS undergoing DMT.
Substances chimiques
teriflunomide
1C058IKG3B
Cladribine
47M74X9YT5
Natalizumab
0
COVID-19 Vaccines
0
Interferon-gamma
82115-62-6
Alemtuzumab
3A189DH42V
Dimethyl Fumarate
FO2303MNI2
Fingolimod Hydrochloride
G926EC510T
Antibodies
0
Antibodies, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3789-3798Informations de copyright
© 2023 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
Références
Thomas SJ, Moreira ED, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine through 6 months. N Engl J Med. 2021;385(19):1761-1773. doi:10.1056/nejmoa2110345
Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403-416. doi:10.1056/nejmoa2035389
Zhang Z, Mateus J, Coelho CH, et al. Humoral and cellular immune memory to four COVID-19 vaccines. Cell. 2022;185(14):2434-2451.e17. doi:10.1016/j.cell.2022.05.022
Sekine T, Perez-Potti A, Rivera-Ballesteros O, et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell. 2020;183(1):158-168.e14. doi:10.1016/j.cell.2020.08.017
Painter MM, Mathew D, Goel RR, et al. Rapid induction of antigen-specific CD4+ T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination. Immunity. 2021;54(9):2133-2142.e3. doi:10.1016/j.immuni.2021.08.001
Sahin U, Muik A, Derhovanessian E, et al. COVID-19 vaccine BNT162b1 elicits human antibody and Th1 T cell responses. Nature. 2020;586(7830):594-599. doi:10.1038/s41586-020-2814-7
Goletti D, Petrone L, Manissero D, et al. The potential clinical utility of measuring severe acute respiratory syndrome coronavirus 2-specific T-cell responses. Clin Microbiol Infect. 2021;27(12):1784-1789. doi:10.1016/j.cmi.2021.07.005
Crotty S. Hybrid immunity. Science. 2021;372(6549):1392-1393. doi:10.1126/science.abj2258
Zollner A, Watschinger C, Rössler A, et al. B and T cell response to SARS-CoV-2 vaccination in health care professionals with and without previous COVID-19. EBioMedicine. 2021;70:70. doi:10.1016/j.ebiom.2021.103539
Hall V, Foulkes S, Insalata F, et al. Protection against SARS-CoV-2 after COVID-19 vaccination and previous infection. N Engl J Med. 2022;386(13):1207-1220. doi:10.1056/nejmoa2118691
Kappos L, Mehling M, Arroyo R, et al. Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis. Neurology. 2015;84(9):872-879. doi:10.1212/WNL.0000000000001302
Metze C, Winkelmann A, Loebermann M, et al. Immunogenicity and predictors of response to a single dose trivalent seasonal influenza vaccine in multiple sclerosis patients receiving disease-modifying therapies. CNS Neurosci Ther. 2019;25(2):245-254. doi:10.1111/cns.13034
Ciotti JR, Valtcheva MV, Cross AH. Effects of MS disease-modifying therapies on responses to vaccinations: a review. Mult Scler Relat Disord. 2020;45:102439. doi:10.1016/j.msard.2020.102439
Apostolidis SA, Kakara M, Painter MM, et al. Cellular and Humoral Immune Responses Following SARS-CoV-2 MRNA Vaccination in Patients with Multiple Sclerosis on Anti-CD20 Therapy. Vol 27. Springer; 2021. doi:10.1038/s41591-021-01507-2
Brill L, Rechtman A, Zveik O, et al. Humoral and T-cell response to SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab. JAMA Neurol. 2021;78(12):1510-1514. doi:10.1001/jamaneurol.2021.3599
Asplund Högelin K, Ruffin N, Pin E, et al. B-cell repopulation dynamics and drug pharmacokinetics impact SARS-CoV-2 vaccine efficacy in anti-CD20-treated multiple sclerosis patients. Eur J Neurol. 2022;29:1-31. doi:10.1111/ene.15492
Achiron A, Mandel M, Gurevich M, et al. Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod. J Neurol. 2022;269(5):2286-2292. doi:10.1007/s00415-022-11030-0
Pitzalis M, Idda ML, Lodde V, et al. Effect of different disease-modifying therapies on humoral response to BNT162b2 vaccine in Sardinian multiple sclerosis patients. Front Immunol. 2021;12:1-9. doi:10.3389/fimmu.2021.781843
Tallantyre EC, Vickaryous N, Anderson V, et al. COVID-19 vaccine response in people with multiple sclerosis. Ann Neurol. 2022;91(1):89-100. doi:10.1002/ana.26251
Sabatino JJ, Mittl K, Rowles WM, et al. Multiple sclerosis therapies differentially affect SARS-CoV-2 vaccine-induced antibody and T cell immunity and function. JCI Insight. 2022;7(4):e156978. doi:10.1172/jci.insight.156978
Tortorella C, Aiello A, Gasperini C, et al. Humoral- and T-cell-specific immune responses to SARS-CoV-2 mRNA vaccination in patients with MS using different disease-modifying therapies. Neurology. 2022;98:e541-e554. doi:10.1212/WNL.0000000000013108
Iannetta M, Landi D, Cola G, et al. B- and T-cell responses after SARS-CoV-2 vaccination in patients with multiple sclerosis receiving disease modifying therapies: immunological patterns and clinical implications. Front Immunol. 2022;12:1-11. doi:10.3389/fimmu.2021.796482
Bock H, Juretzek T, Handreka R, et al. Humoral and cellular immune responses to SARS CoV-2 vaccination in people with multiple sclerosis and NMOSD patients receiving immunomodulatory treatments. Mult Scler Relat Disord. 2022;59:103554. doi:10.1016/j.msard.2022.103554
Trümpelmann S, Schulte-Mecklenbeck A, Steinberg OV, et al. Impact of disease-modifying therapies on humoral and cellular immune-responses following SARS-CoV-2 vaccination in MS patients. Clin Transl Sci. 2022;15(7):1606-1612. doi:10.1111/cts.13256
Meyer-Arndt L, Braun J, Fauchere F, et al. SARS-CoV-2 mRNA vaccinations fail to elicit humoral and cellular immune responses in patients with multiple sclerosis receiving fingolimod. J Neurol Neurosurg Psychiatry. 2022;93:960-971. doi:10.1136/jnnp-2022-329395
Zabalza A, Arrambide G, Otero-Romero S, et al. Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases? Mult Scler J. 2022;28(7):1138-1145. doi:10.1177/13524585221089540
Habek M, Željko C, Savić Mlakar A, et al. Humoral and cellular immunity in convalescent and vaccinated COVID-19 people with multiple sclerosis: effects of disease modifying therapies. Mult Scler Relat Disord. 2022;59:103682. doi:10.1016/j.msard.2022.103682
Kister I, Curtin R, Pei J, et al. Hybrid and vaccine-induced immunity against SAR-CoV-2 in MS patients on different disease-modifying therapies. Ann Clin Transl Neurol. 2022;9(10):1643-1659. doi:10.1002/acn3.51664
Rudberg AS, Havervall S, Månberg A, et al. SARS-CoV-2 exposure, symptoms and seroprevalence in healthcare workers in Sweden. Nat Commun. 2020;11(1):1-8. doi:10.1038/s41467-020-18848-0
Asplund Högelin K, Ruffin N, Pin E, et al. Development of humoral and cellular immunological memory against SARS-CoV-2 despite B cell depleting treatment in multiple sclerosis. iScience. 2021;24(9):103078. doi:10.1016/j.isci.2021.103078
Bao K, Reinhardt RL. The differential expression of IL-4 and IL-13 and its impact on type-2 immunity. Cytokine. 2015;75(1):25-37. doi:10.1016/j.cyto.2015.05.008
Gao Y, Cai C, Wullimann D, et al. Immunodeficiency syndromes differentially impact the functional profile of SARS-CoV-2-specific T cells elicited by mRNA vaccination. Immunity. 2022;55:1732. doi:10.1016/j.immuni.2022.07.005
Lucas C, Wong P, Klein J, et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature. 2020;584(7821):463-469. doi:10.1038/s41586-020-2588-y
Donlan AN, Sutherland TE, Marie C, et al. IL-13 is a driver of COVID-19 severity. JCI Insight. 2021;6(15):e150107. doi:10.1172/jci.insight.150107
Meltendorf S, Vogel K, Thurm C, et al. IL-13 determines specific IgE responses and SARS-CoV-2 immunity after mild COVID-19 and novel mRNA vaccination. Eur J Immunol. 2022;52(12):1972-1979. doi:10.1002/eji.202249951
Sormani MP, De Rossi N, Schiavetti I, et al. Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis. Ann Neurol. 2021;89(4):780-789. doi:10.1002/ana.26028
Sullivan R, Kilaru A, Hemmer B, et al. COVID-19 infection in fingolimod- or siponimod-treated patients: case series. Neurol Neuroimmunol Neuroinflamm. 2021;9(1):1-7. doi:10.1212/NXI.0000000000001092
Longinetti E, Bower H, McKay KA, et al. COVID-19 clinical outcomes and DMT of MS patients and population-based controls. Ann Clin Transl Neurol. 2022;9(9):1449-1458. doi:10.1002/acn3.51646
Schiavetti I, Cordioli C, Stromillo ML, et al. Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies. Mult Scler J. 2022;28:1-6. doi:10.1177/13524585221102918
Garjani A, Patel S, Bharkhada D, et al. Impact of mass vaccination on SARS-CoV-2 infections among multiple sclerosis patients taking immunomodulatory disease-modifying therapies in England. Mult Scler Relat Disord. 2021;2022(57):103458. doi:10.1016/j.msard.2021.103458
Achtnichts L, Ovchinnikov A, Jakopp B, et al. SARS-CoV-2 mRNA vaccination in people with multiple sclerosis treated with fingolimod: protective humoral immune responses may develop after the preferred third shot. Vaccine. 2022;10(2):4-11. doi:10.3390/vaccines10020341
Maglione A, Morra M, Meroni R, Matta M, Clerico M, Rolla S. Humoral response after the booster dose of anti-SARS-CoV-2 vaccine in multiple sclerosis patients treated with high-efficacy therapies. Mult Scler Relat Disord. 2022;61:3-5. doi:10.1016/j.msard.2022.103776
Aiello A, Coppola A, Ruggieri S, et al. Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies. J Neurol Neurosurg Psychiatry. 2022;94:1-10. doi:10.1136/jnnp-2022-330175
Grothe C, Steffen F, Bittner S. Humoral immune response and lymphocyte levels after complete vaccination against COVID-19 in a cohort of multiple sclerosis patients treated with cladribine tablets. J Cent Nerv Syst Dis. 2021;13:117957352110601. doi:10.1177/11795735211060118
Achiron A, Mandel M, Dreyer-Alster S, et al. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther Adv Neurol Disord. 2021;14:14. doi:10.1177/17562864211012835